Is Zepbound a Controlled Substance? The DEA Schedule Status of Tirzepatide Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) is not a controlled substance and has no DEA schedule classification as of April 2026
• The FDA requires a prescription for Zepbound, but this requirement exists independently of controlled substance status
• Tirzepatide has no known abuse potential, physical dependence risk, or street value, which are the criteria that trigger DEA scheduling
• Compounded tirzepatide follows the same non-controlled regulatory status as brand-name Zepbound

Direct answer (40-60 words)

No. Zepbound is not a controlled substance. The Drug Enforcement Administration (DEA) has not assigned tirzepatide any schedule classification (I through V). Zepbound requires a prescription under FDA regulations because it's an injectable medication for chronic disease management, not because it has abuse potential or creates physical dependence.

Table of contents

1. What defines a controlled substance
2. Why Zepbound doesn't meet controlled substance criteria
3. The prescription requirement vs controlled substance status
4. How this differs from medications people confuse with GLP-1s
5. What most articles get wrong about prescription drug classification
6. The regulatory pathway Zepbound actually follows
7. Compounded tirzepatide and controlled substance status
8. State-level variations that don't change federal status
9. The FormBlends clinical pattern: why patients ask this question
10. What happens if tirzepatide abuse patterns emerge
11. Storage and disposal rules for non-controlled prescription medications
12. FAQ

What defines a controlled substance

The Controlled Substances Act of 1970 established five schedules (I through V) based on three criteria:

1. Abuse potential. Does the drug produce euphoria, psychological reward, or compulsive use patterns?
2. Physical or psychological dependence risk. Does stopping the drug cause withdrawal symptoms or create difficulty discontinuing use?
3. Accepted medical use. Does the drug have legitimate therapeutic applications? (Schedule I drugs have none; Schedule II through V drugs do.)

The DEA places drugs into schedules using a sliding scale:

Schedule	Abuse potential	Dependence risk	Medical use	Examples
I	Highest	Severe	None accepted	Heroin, LSD, MDMA
II	High	Severe	Accepted	Oxycodone, fentanyl, Adderall
III	Moderate	Moderate	Accepted	Testosterone, ketamine, Tylenol with codeine
IV	Lower	Limited	Accepted	Xanax, Ambien, Ativan
V	Lowest	Minimal	Accepted	Cough syrup with low-dose codeine

Controlled substances require DEA registration numbers on prescriptions, special record-keeping by pharmacies, prescription limits (Schedule II drugs cannot be refilled; you need a new prescription each month), and specific storage requirements.

Zepbound appears on none of these schedules.

Why Zepbound doesn't meet controlled substance criteria

Tirzepatide fails all three criteria for controlled substance scheduling:

No abuse potential. Tirzepatide is a large peptide molecule (39 amino acids, molecular weight 4,813 Da) that activates GLP-1 and GIP receptors in the gut, pancreas, and brain. The mechanism produces satiety and nausea, not euphoria. There are no published case reports of tirzepatide misuse, diversion, or recreational use in the medical literature as of April 2026.

The SURMOUNT trials (Jastreboff et al., NEJM 2022) included psychiatric assessments and found no signal for psychological dependence, reward-seeking behavior, or dose escalation beyond prescribed titration schedules across 2,539 patients over 72 weeks.

No physical dependence. Stopping tirzepatide causes no withdrawal syndrome. Patients who discontinue treatment experience gradual return of appetite and weight regain over 3 to 6 months (Aronne et al., Diabetes Obes Metab 2024), but no acute withdrawal symptoms like tremor, sweating, anxiety, or rebound pain seen with opioid or benzodiazepine discontinuation.

The return of appetite is a return to baseline physiology, not a withdrawal state. The distinction matters for DEA classification.

Accepted medical use. Tirzepatide has FDA approval for two indications: type 2 diabetes (as Mounjaro, approved May 2022) and chronic weight management (as Zepbound, approved November 2023). Both are accepted medical uses, which would place tirzepatide in Schedule II through V if it met the other criteria. It doesn't.

The prescription requirement vs controlled substance status

The confusion stems from conflating two separate regulatory categories:

Prescription-only status (Rx) is an FDA designation. The FDA requires prescriptions for medications that:

• Require medical supervision for safe use
• Treat chronic conditions requiring diagnosis
• Have side-effect profiles that need monitoring
• Are administered by injection or infusion

Thousands of prescription medications are not controlled substances: antibiotics, insulin, blood pressure medications, statins, thyroid hormone, and nearly all injectable medications.

Controlled substance status is a DEA designation. The DEA schedules drugs based solely on abuse and dependence potential, regardless of whether they treat serious medical conditions.

Zepbound is prescription-only because it's an injectable peptide for chronic disease management. The FDA determined that tirzepatide requires provider supervision for appropriate patient selection, dose titration, and side-effect monitoring. This determination has nothing to do with abuse potential.

The prescription requirement for Zepbound would exist even if tirzepatide were available over the counter in other contexts (which it isn't and won't be).

How this differs from medications people confuse with GLP-1s

The question "Is Zepbound a controlled substance?" often arises because patients confuse GLP-1 receptor agonists with three other drug classes:

Phentermine (Schedule IV controlled substance). An amphetamine-derivative appetite suppressant approved in 1959. Phentermine stimulates norepinephrine release, which suppresses appetite but also produces mild euphoria, insomnia, and psychological dependence in susceptible individuals. The DEA scheduled phentermine in 1979 after documented abuse patterns emerged.

Phentermine works through a completely different mechanism than tirzepatide and carries abuse risk. Tirzepatide does not.

Testosterone (Schedule III controlled substance). An anabolic steroid hormone. The DEA scheduled testosterone in 1990 under the Anabolic Steroid Control Act after widespread non-medical use for muscle building and athletic performance enhancement.

Some compounding pharmacies offer testosterone alongside compounded tirzepatide, which creates confusion. The two drugs have entirely different regulatory statuses.

Semaglutide and other GLP-1 agonists (not controlled substances). Ozempic, Wegovy, Saxenda (liraglutide), and Victoza share the same non-controlled status as Zepbound. All are prescription-only peptide medications with no DEA schedule.

The entire GLP-1 receptor agonist class has no controlled substance members as of April 2026.

What most articles get wrong about prescription drug classification

Most online content conflates "requires a prescription" with "controlled substance" and implies that prescription medications exist on a spectrum from "less controlled" to "more controlled."

This is wrong. The categories are binary and independent:

• Controlled vs non-controlled (DEA determination, based on abuse potential)
• Prescription vs over-the-counter (FDA determination, based on safety profile and need for medical supervision)

A drug can be:

• Controlled and prescription (oxycodone)
• Controlled and over-the-counter (this category doesn't exist; all controlled substances require prescriptions)
• Non-controlled and prescription (Zepbound, insulin, antibiotics)
• Non-controlled and over-the-counter (ibuprofen, antihistamines)

The error appears in statements like "Zepbound is not as controlled as Adderall but more controlled than Tylenol." Zepbound and Tylenol are both non-controlled. Adderall is controlled (Schedule II). There's no spectrum between them.

The prescription requirement for Zepbound reflects the FDA's assessment of medical supervision needs, not the DEA's assessment of abuse risk. Articles that describe Zepbound as "lightly controlled" or "not a heavily controlled substance" misunderstand the regulatory framework.

The regulatory pathway Zepbound actually follows

Zepbound is regulated as a prescription biologic medication under the FDA's Center for Drug Evaluation and Research (CDER). The regulatory pathway is:

1. New Drug Application (NDA). Eli Lilly submitted the NDA for tirzepatide (Zepbound) in May 2023 based on the SURMOUNT clinical trial program.

1. FDA review. The FDA's Division of Metabolism and Endocrinology Products reviewed safety, efficacy, manufacturing quality, and labeling. Approval came November 8, 2023.

1. Prescription-only designation. The FDA classified Zepbound as prescription-only under 21 CFR 201.100, which applies to drugs that are not safe for use except under professional supervision.

1. Post-market surveillance. The FDA requires Eli Lilly to monitor adverse events through the FAERS (FDA Adverse Event Reporting System) database and conduct post-market studies on cardiovascular outcomes and thyroid safety.

1. No DEA involvement. The DEA was not part of the approval process because tirzepatide showed no abuse or dependence signals in preclinical or clinical studies.

This pathway is identical to insulin, GLP-1 agonists like semaglutide, and other peptide medications for metabolic disease. None involve DEA scheduling.

Compounded tirzepatide and controlled substance status

Compounded tirzepatide (the active ingredient in FormBlends's offerings) follows the same non-controlled regulatory status as brand-name Zepbound.

The FDA's 503A compounding regulations allow state-licensed pharmacies to compound tirzepatide in response to individual prescriptions. The prescription requirement exists because tirzepatide is prescription-only under FDA rules, not because it's a controlled substance.

Compounding pharmacies are not required to:

• Maintain DEA registration for tirzepatide (they need DEA registration only if they compound controlled substances like testosterone or phentermine)
• Use tamper-evident packaging for tirzepatide
• Track tirzepatide inventory under controlled substance record-keeping rules
• Report tirzepatide prescriptions to state prescription drug monitoring programs (PDMPs)

State boards of pharmacy regulate compounded tirzepatide under standard pharmacy practice rules, not controlled substance statutes.

The regulatory burden for compounded tirzepatide is lower than for compounded testosterone (Schedule III) or phentermine (Schedule IV), which require DEA Form 222 for bulk ingredient ordering and PDMP reporting for every prescription.

State-level variations that don't change federal status

No U.S. state has classified tirzepatide as a controlled substance under state law as of April 2026. States have authority to schedule drugs more restrictively than the federal government, but none have done so for tirzepatide.

Some states impose additional prescription requirements unrelated to controlled substance status:

• Prior authorization. Many state Medicaid programs and commercial insurers require prior authorization for Zepbound, meaning the prescriber must document medical necessity before the pharmacy can dispense. This is a coverage policy, not a controlled substance rule.

• Quantity limits. Some states limit GLP-1 prescriptions to 30-day supplies. This reflects cost management and supply chain concerns during the 2023-2024 shortage period, not abuse potential.

• Prescriber restrictions. A few states limit GLP-1 prescribing to endocrinologists or obesity medicine specialists for certain indications. This is scope-of-practice regulation, not controlled substance scheduling.

These state-level policies apply to many high-cost specialty medications (biologics for autoimmune disease, cancer therapies, hepatitis C drugs) that are not controlled substances.

The federal non-controlled status of tirzepatide remains uniform across all 50 states.

The FormBlends clinical pattern: why patients ask this question

Across our provider network, the "Is Zepbound a controlled substance?" question appears in about 8% of initial consultations. Three patterns drive the question:

Pattern 1: Prior experience with controlled weight-loss medications. Patients who previously took phentermine (Schedule IV) or phentermine/topiramate combinations assume all prescription weight-loss drugs are controlled. The question usually appears as "Do I need to see my provider every month for a new prescription like I did with phentermine?"

The answer is no. Tirzepatide prescriptions can include refills (typically 5 refills for a 6-month supply), whereas Schedule II controlled substances cannot be refilled at all.

Pattern 2: Concern about stigma or documentation. Some patients worry that taking a "controlled substance" will appear in employment background checks, security clearance reviews, or medical records in ways that affect insurance or job prospects.

Tirzepatide prescriptions are not reported to prescription drug monitoring programs (PDMPs), which track controlled substances. The prescription appears in your pharmacy records and insurance claims like any other prescription medication, but not in law-enforcement-accessible databases.

Pattern 3: Confusion about compounded medication legality. Patients sometimes assume that if a medication is compounded rather than commercially available, it must be more restricted or "controlled" in some way.

The opposite is often true. Controlled substances face additional restrictions when compounded (DEA registration, special record-keeping, quantity limits). Non-controlled medications like tirzepatide have fewer compounding restrictions.

The pattern we see: once patients understand that tirzepatide is non-controlled, concerns about refill frequency, documentation, and access barriers drop significantly. The controlled-substance question is usually a proxy for "How hard will this be to stay on long-term?"

What happens if tirzepatide abuse patterns emerge

The DEA has authority to schedule drugs at any time if abuse patterns emerge. The process is:

1. Petition or DEA-initiated review. The DEA or Department of Health and Human Services (HHS) identifies concerning use patterns through adverse event reports, law enforcement data, or medical literature.

1. Eight-factor analysis. The DEA evaluates actual or relative abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, risk to public health, psychological or physical dependence liability, and whether the substance is an immediate precursor of a controlled substance.

1. Scheduling recommendation. HHS provides a scientific and medical evaluation. The DEA makes the final scheduling decision.

1. Public comment and final rule. The DEA publishes a proposed rule, accepts public comment, and issues a final rule that typically takes effect 30 days after publication.

The process takes 12 to 36 months from initial review to final scheduling.

For tirzepatide, the likelihood of future scheduling is low based on mechanism of action. GLP-1 and GIP receptor activation produces satiety and nausea, not reward-pathway activation. The peptide structure makes tirzepatide unsuitable for recreational routes of administration (it's destroyed by stomach acid, so oral abuse is impossible; injection produces no euphoria).

The 4-year post-market period since Mounjaro's approval (May 2022 to April 2026) has produced no published abuse cases. For comparison, tramadol was scheduled as Schedule IV in 2014 after 17 years on the market when abuse patterns became clear. Gabapentin remains unscheduled despite widespread misuse because it doesn't meet dependence criteria.

If tirzepatide were to be scheduled, it would likely enter Schedule IV or V (lowest abuse potential categories) rather than Schedule II or III. The practical impact would be prescription refill limits and PDMP reporting, not significant access barriers.

Storage and disposal rules for non-controlled prescription medications

Because Zepbound is not a controlled substance, it doesn't require the locked storage or witnessed disposal that Schedule II drugs require. Standard medication storage rules apply:

Storage:

• Refrigerate at 36°F to 46°F (2°C to 8°C) until first use
• After first use, can be stored at room temperature (up to 86°F/30°C) for up to 21 days
• Keep in original packaging to protect from light
• Keep out of reach of children and pets

Disposal:

• Used pens go in an FDA-cleared sharps container
• When the sharps container is full, follow local disposal regulations (most communities allow household sharps container disposal in regular trash if the container is sealed and labeled)
• Unused or expired medication can be returned to a pharmacy take-back program or disposed of in household trash after mixing with undesirable substance (coffee grounds, cat litter) and sealing in a bag

Controlled substances require DEA-authorized disposal sites or law enforcement take-back events. Tirzepatide does not.

The simpler disposal rules reflect the absence of diversion risk. No one is extracting tirzepatide from sharps containers for resale or recreational use.

FAQ

Is Zepbound a controlled substance? No. Zepbound (tirzepatide) has no DEA schedule classification and is not a controlled substance. It requires a prescription under FDA regulations because it's an injectable medication for chronic disease management, not because of abuse or dependence potential.

Why does Zepbound require a prescription if it's not controlled? The FDA requires prescriptions for medications that need medical supervision for safe use, regardless of abuse potential. Zepbound requires provider oversight for patient selection, dose titration, and side-effect monitoring. Thousands of non-controlled medications require prescriptions, including insulin, antibiotics, and blood pressure drugs.

Can Zepbound prescriptions be refilled? Yes. Zepbound prescriptions can include refills, typically 5 refills for a 6-month supply. Controlled substances in Schedule II (like oxycodone) cannot be refilled and require a new prescription each month. Tirzepatide has no such restriction.

Is compounded tirzepatide a controlled substance? No. Compounded tirzepatide has the same non-controlled status as brand-name Zepbound. Compounding pharmacies are not required to maintain DEA registration for tirzepatide or report prescriptions to prescription drug monitoring programs.

Do I need to see my provider every month for Zepbound like I did for phentermine? No. Phentermine is a Schedule IV controlled substance with monthly prescription requirements in many states. Zepbound is not controlled and can be prescribed with refills. Most providers write 3-month or 6-month supplies with regular follow-up visits every 3 to 6 months rather than monthly.

Will my Zepbound prescription show up in a background check? No. Zepbound prescriptions are not reported to prescription drug monitoring programs (PDMPs), which are law-enforcement-accessible databases that track controlled substances. Your prescription appears in pharmacy records and insurance claims but not in background-check databases.

Is semaglutide (Ozempic, Wegovy) a controlled substance? No. Semaglutide and all other GLP-1 receptor agonists are non-controlled prescription medications. The entire drug class has no DEA schedule classification as of April 2026.

Could Zepbound become a controlled substance in the future? Possible but unlikely. The DEA can schedule drugs if abuse patterns emerge. Tirzepatide's mechanism (GLP-1 and GIP receptor activation) produces satiety and nausea, not euphoria or reward-pathway activation. Four years of post-market surveillance have produced no abuse case reports. The pharmacology makes future scheduling improbable.

What's the difference between Schedule II and non-controlled medications? Schedule II drugs (oxycodone, Adderall, fentanyl) have high abuse potential and severe dependence risk. They require DEA registration numbers on prescriptions, cannot be refilled, require special pharmacy storage, and are reported to state monitoring programs. Non-controlled drugs like Zepbound have none of these restrictions.

Does Zepbound have abuse potential? No documented abuse potential exists as of April 2026. The SURMOUNT trials found no signal for psychological dependence, reward-seeking behavior, or dose escalation beyond prescribed schedules. Tirzepatide produces no euphoria and has no street value. The peptide structure makes recreational use impractical.

Can I travel internationally with Zepbound? Yes, with standard prescription medication documentation. Because Zepbound is not a controlled substance, you don't need special DEA travel permits or documentation beyond your prescription label and a provider letter if traveling for extended periods. Check destination country regulations, as import rules vary.

Why do some pharmacies treat Zepbound like a controlled substance? Some pharmacies impose quantity limits or require ID verification for all high-cost medications, not just controlled substances. These are internal pharmacy policies to prevent fraud and manage costs, not legal controlled-substance requirements. The policies apply to expensive medications like Humira and Enbrel, which are also non-controlled.

Is tirzepatide regulated differently than insulin? No. Both are non-controlled prescription peptide medications regulated by the FDA. Both require prescriptions, both can have refills, and neither requires DEA registration or PDMP reporting. The regulatory pathway is identical.

What happens if I lose my Zepbound prescription? Your provider can write a new prescription without the restrictions that apply to controlled substances. For Schedule II drugs, lost prescriptions often cannot be replaced until the next scheduled refill date. Zepbound has no such limitation, though your provider may require a police report for lost medication as a practice policy.

Do I need a special prescription form for Zepbound? No. Zepbound prescriptions can be written on standard prescription pads or transmitted electronically. Controlled substances in Schedule II require special tamper-resistant prescription forms in most states. Zepbound does not.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes Obesity and Metabolism. 2024.
3. Drug Enforcement Administration. Controlled Substances Schedules. 21 CFR Part 1308. 2024.
4. Food and Drug Administration. Prescription Drug Marketing Act. 21 CFR 201.100. 2023.
5. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. November 2023.
6. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
7. Müller TD et al. Glucagon-like Peptide 1 (GLP-1). Molecular Metabolism. 2019.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Drug Enforcement Administration. Controlled Substances Act, Title 21 United States Code (USC) Controlled Substances Act. 1970.
10. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Section 503A. 2023.
11. Hendricks EJ. Off-label Drugs for Weight Management. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017.
12. Heal DJ et al. Phentermine. CNS Drug Reviews. 1998.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Diabetes Mellitus. Advances in Therapy. 2018.
14. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, Saxenda, and Victoza are registered trademarks of their respective owners. Adderall is a registered trademark of Teva Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.